Ribosomal protein L21 pseudogene 92 (RPL21P92)

Ribosomal protein L21 pseudogene 92 (RPL21P92) is a processed pseudogene derived from the ribosomal protein L21 (RPL21) gene. Pseudogenes are genomic DNA sequences similar to normal genes but are nonfunctional; they usually arise from gene duplication or retrotransposition events and accumulate disabling mutations preventing them from encoding a functional protein. RPL21P92 does not produce a functional protein and does not play a role as a drug target, biomarker, or known mediator of disease. As a pseudogene, it may be used in genome studies as a genomic marker for evolutionary or structural analysis, but it has no recognized biological or pharmacological function. Unlike the actual ribosomal protein L21 (RPL21), which is a structural component of the 60S ribosomal subunit and involved in protein synthesis, RPL21P92 is specifically annotated as a nonfunctional sequence. There is no evidence in the current literature or databases indicating that RPL21P92 has any protein-coding, regulatory, or therapeutic target role. No drugs, clinical biomarkers, or known disease associations are linked to RPL21P92. If the intention is to reference an active protein or therapeutic target, then RPL21 (ribosomal protein L21) is the relevant gene. In contrast, RPL21P92 should not be considered a therapeutic target, drug receptor, or functional biological molecule.

Other names

RPL21_38_1051RPL21P92